Singapore healthtech Respiree secures $11.6M Series A to scale AI-driven patient monitoring across US, APAC, and GCC markets.

Key Details
- Series A led by We Venture Capital and ClavystBio, with $11.6 million raised including participation from Mayo Clinic and existing investors.
- Funds will expand Respiree’s US headquarters in Houston’s Texas Medical Center and accelerate growth in Asia-Pacific and Gulf Cooperation Council (GCC) markets.
- Partnership with Roche Diagnostics to pilot programs in APAC; platform automates patient monitoring and care pathway management using AI/ML.

Why It Matters for Gulf–ASEAN
Respiree’s expansion strategy into the GCC and Southeast Asia highlights the increasing convergence of healthtech innovation between Gulf and ASEAN markets, offering new opportunities for collaborative healthcare solutions and investments leveraging AI to address workforce constraints and patient care efficiency.

What It Means for GAE Community
- Monitor emerging healthtech startups enabling data-driven clinical decision-making across GCC and ASEAN healthcare systems.
- Explore partnership and investment opportunities with AI health platforms expanding across Gulf–ASEAN corridors.
- Leverage Respiree’s growing footprint and clinical partnerships as a model for scalable cross-regional medtech collaboration.

Source
Read the full article via TechNode Global